- Conditions
- Atopic Dermatitis
- Interventions
- nemolizumab (CIM331), Placebo
- Drug · Other
- Lead sponsor
- Chugai Pharmaceutical
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 18
- States / cities
- Anniston, Alabama • San Diego, California • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced May 21, 2026, 11:09 PM EDT